A. Nahimana

Discipline

Histoire, Philosophie et Sociologie des sciences (2)

Type de document

Articles (20)

Co-auteur

Date

Source

Mot-clé

Treatment (12) Human beings (12) Cells (9) Patients (8) Inhibition (8) Patients (8) spectacle (7) enzyme (7) Nicotinamide (7) Mice (7) Leukemia (7) Cancer cells (7) Animals (7) thérapie (6) modèle (6) ligne (6) Therapeutics (6) Example (6) Cell death (6) roman (6) biosynthèse (5) effet (5) cancer (5) Development (5) Cancer (5) Inhibitors (5) Pneumonia (5) Lymphomas (5) Evidence (5) Cancer (5)

Documents écrit par A. Nahimana (20) | parle de A. Nahimana (0)

Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.
S. Fratta et al. (15 mars 2023)
Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies.
P. Biniecka et al. (16 févr. 2023)
Nicotinaldehyde, a Novel Precursor of NAD Biosynthesis, Abrogates the Anti-Cancer Activity of an NAD-Lowering Agent in Leukemia.
S. Matsumoto et al. (27 janv. 2023)
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
M.S. Ghanem et al. (10 juil. 2022)
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
O. ElMokh et al. (8 avr. 2022)
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent.
A.J. Cloux et al. (19 nov. 2019)
Experimental Drainage Device to Reduce Lymphoedema in a Rat Model.
V. Triacca et al.
The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.
N. Vannini et al. (7 mars 2019)
Activation of Bone Marrow-Derived Cells Angiotensin (Ang) II Type 1 Receptor by Ang II Promotes Atherosclerotic Plaque Vulnerability.
M. Pellegrin et al. (4 sept. 2018)
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
A. Cagnetta et al.
The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner.
M. Heulot et al. (27 sept. 2016)
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
G. Sociali et al. (19 janv. 2016)
A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.
C.S. Breton et al. (2014)
A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
V. Ginet et al. (2014)
A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants
A. Nahimana et al. (2011)
Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations.
P.M. Hauser et al. (2010)
Molecular evidence of Pneumocystis transmission in pediatric transplant unit.
B. Höcker et al.
Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients.
M. Rabodonirina et al. (2004)
Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients
A. Nahimana et al.
Prophylaxis failure is associated with a specific Pneumocystis carinii genotype.
P.M. Hauser et al.